MXCT Oct 2024 5.000 call
| Previous Close | 0.7900 |
| Open | 0.7900 |
| Bid | 0.4000 |
| Ask | 0.6500 |
| Strike | 5.00 |
| Expire Date | 2024-10-18 |
| Day's Range | 0.7900 - 0.7900 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 10 |
GlobeNewswireMaxCyte to Participate in William Blair 44th Annual Growth Stock Conference
ROCKVILLE, Md., May 29, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced Company management will participate at the William Blair 44th Annual Growth Stock Conference on Wednesday, June 5th at 2:40 pm CT. A live and archived webcast of
Simply Wall St.With 64% ownership of the shares, MaxCyte, Inc. (LON:MXCT) is heavily dominated by institutional owners
Key Insights Significantly high institutional ownership implies MaxCyte's stock price is sensitive to their trading...
- GlobeNewswire
MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development
Legend Biotech obtains license to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its non-viral engineered pipeline portfolio across a variety of cell types including T cells, Gamma-Delta T cells and NK Cells.ROCKVILLE, Md., May 22, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell
